Insights

PTAB Institutes IPR Proceedings Against Mayne Pharma’s Antifungal Formulation Patent, <i>PTAB Litigation Blog</i>

PTAB Institutes IPR Proceedings Against Mayne Pharma’s Antifungal Formulation Patent, PTAB Litigation Blog

Visit the Jones Day PTAB Litigation Blog.

The PTAB instituted an IPR on claims of Mayne Pharma International Pty Ltd.’s (“Mayne”) U.S. Patent No. 6,881,745 B2 covering formulations of azole antifungals in IPR2016-01186.  In response to Merck Sharp & Dohme Corp.’s (“Merck”) Petition, the PTAB instituted review of some claims on anticipation grounds, and of all challenged claims on the grounds of obviousness.

Read the full article at ptablitigationblog.com.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.